Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor

Molecular Cancer Research

Volumn 7, Issue 1, 2009, Pages 67-78

  Zhang, Jin ^a   Chen, Xinbin ^a   Chen, Xiangling ^a   Kent, Michael S ^a   Rodriguez, Carlos O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR; ISOPROTEIN; NUTLIN 3; PROTEIN 53BP1; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P63; PROTEIN P73; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DOG; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CAMPTOTHECIN; CELL LINE; CELL LINE, TUMOR; CONSERVED SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOGS; DOXORUBICIN; HUMANS; KIDNEY; MELANOMA; MICE; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEIN P53;

CANIS FAMILIARIS;

EID: 58649099834     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0347     Document Type: Article

References (34)

1. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
2. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.
3. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
4. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
5. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398: 708-13.
6. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398: 714-8.
7. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
8. Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 2000;37:54-61.
9. Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Miyoshi N, Hayashi T. Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 1999; 61:27-32.
10. Ginn PE, Fox LE, Brower JC, Gaskin A, Kurzman ID, Kubilis PS. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet Pathol 2000;37: 33 -9.
11. Gordon IK, Ye F, Kent MS. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 2008;69: 1079-84.
12. Chen SC, Chen CH, Chern CL, et al. p-Phenylenediamine induces p53- mediated apoptosis in Mardin-Darby canine kidney cells. Toxicol In Vitro 2006; 20:801 -7.
13. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14:1815-23.
14. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
15. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
16. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
17. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
18. Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J Cell Biol 2001;153:613-20.
19. Anderson L, Henderson C, Adachi Y. Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol Cell Biol 2001;21:1719-29.
20. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron de Fromentel C. The expression of TA and δNp63 are regulated by different mechanisms in liver cells. Oncogene 2005;24:512-9.
21. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004;61:822-42.
22. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 1991;4:35 -40.
23. Montano X, Shamsher M, Whitehead P, Dawson K, Newton J. Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 1994;9:1455 -9.
24. Roels S, Tilmant K, Ducatelle R. p53 expression and apoptosis in melanomas of dogs and cats. Res Vet Sci 2001;70:19-25.
25. Li H, Wang J, Mor G, Sklar J. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 2008;321:1357 -61.
26. Nozell S, Chen X. p21B, a variant of p21(Waf1/Cip1), is induced by the p53 family. Oncogene 2002;21:1285-94.
27. Gartel AL, Radhakrishnan SK, Serfas MS, Kwon YH, Tyner AL. A novel p21WAF1/CIP1 transcript is highly dependent on p53 for its basal expression in mouse tissues. Oncogene 2004;23:8154-7.
28. Radhakrishnan SK, Gierut J, Gartel AL. Multiple alternate p21 transcripts are regulated by p53 in human cells. Oncogene 2006;25:1812-5.
29. 2/M arrest. J Biol Chem 1996;271: 29556-60.
30. Poon RY, Hunter T. Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells. Oncogene 1998;16:1333-43.
31. Wong NA, Mayer NJ, Anderson CE, et al. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms. Hum Pathol 2003;34:580-8.
32. Yang W, Klos KS, Zhou X, et al. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer 2003;98: 1123-30.
33. Jung EJ, Liu G, Zhou W, Chen X. Myosin VI is a mediator of the p53-dependent cell survival pathway. Mol Cell Biol 2006;26:2175-86.
34. Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 1995;55:4257-63.